FOR IMMEDIATE RELEASE
Sunday, June 17, 2007
NIAID MEDIA AVAILABILITY
Blood-Brain Barrier Breached by New
A major obstacle in the treatment of infections and other diseases of the brain is the blood-brain barrier, which prevents systemically delivered therapeutic drugs from reaching the brain. Grantees of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, have now shown that a short protein (peptide) from the rabies virus can carry a strip of therapeutic material into the brain via intravenous administration. Once delivered to the nerve cells of the brain, the strip, called a small interfering RNA (siRNA), was shown to protect mice from infection caused by the Japanese encephalitis virus (JEV).
Manjunath N. Swamy, M.D., of the CBR Institute for Biomedical Research and Harvard Medical School in Boston, and his colleagues used JEV to infect the brains of mice. They then injected the antiviral siRNA bound to the rabies peptide through the tail veins in one group of mice, while other mice served as control groups. All the mice in the control groups died from JEV infection; in contrast, 80 percent of the mice that got the antiviral siRNA linked to the rabies peptide survived. These experiments demonstrate how the rabies peptide can be used to deliver antiviral siRNA across the blood-brain barrier and into nerve cells in the brain. Once inside brain nerve cells, the antiviral siRNA can silence key viral genes to control the infection. Furthermore, repeated administration of the RNA interference therapy did not trigger inflammation or antibodies to the peptide.
Currently, doctors use various methods to deliver therapeutic drugs directly into the brain. These methods involve invasive procedures that result in only localized delivery around the site of injection. The new research provides a safe and non-invasive method for delivering therapeutic molecules across the blood-brain barrier. It has the potential to be applied to the treatment of a variety of brain infections and diseases. The researchers are now trying to improve the efficacy of this delivery system and to make a stable form of siRNA that might yield even better results.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of
infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News
releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S.
Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research,
and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health ®
back to top
Last Updated June 18, 2007